Cell-Converting Cancer Therapy
Unlike the current cancer therapies including chemotherapy, radiation therapy, targeted therapy and immunotherapy that focuses on killing cancer cells, our innovative SON-DP induced cell-converting cancer therapy centers at reprogramming cancer cells in vivo into transient pluripotent stem cells (tiPSCs) that regain differentiation potentials. Under the differentiating tissue micro-environment, the newly in situ generated tiPSCs quickly re-differentiate into younger healthy resident tissue cells. This new cancer therapy applies a innovative breakthrough strategy for cancer treatment.
A first-in-human Phase I clinical trial of this SON-DP induced cell converting cancer therapy is ongoing in the US to treat solid tumor with the focuses on colorectal, breast, ovary and pancreatic cancers (IND Number: 152226, ClinicalTrials.gov ID: NCT05989724). Our preclinical and clinical data up to-date demonstrated the safety of the SON-DP transcription factor drug and initial therapeutic efficacy of tumor shrinkage and smaller metastatic lesson disappearance.